



# WHAT DO THESE RESULTS MEAN FOR INDIVIDUALS WITH LOW BODY SURFACE AREA, MODERATE PSORIASIS?

For individuals with low body surface area, moderate psoriasis, the study showed that using guselkumab resulted in significant skin clearance. More than 7 in 10 study participants had clear or nearly clear skin at Week 16, and 8 in 10 achieved these results at Week 48.



## WHAT WAS THE PURPOSE OF THIS STUDY?

- The purpose of the study was to evaluate the **efficacy and safety** of guselkumab in participants with **low body surface area, moderate plaque psoriasis**, focusing on skin clearance and safety results through Week 48.




## WHO PARTICIPATED IN THE STUDY AND HOW WAS IT CONDUCTED?

- SPECTREM was a phase 3b, multicenter, randomized, double-blind, placebo-controlled trial with 338 participants. It evaluated the efficacy and safety of guselkumab in treating moderate plaque psoriasis, using the Investigator's Global Assessment (IGA) and the Psoriasis Area and Severity Index (PASI) over 48 weeks.

### SPECTREM Study Methods

SPECTREM enrolled people with **moderate plaque psoriasis** affecting 2-15% of their total **body surface area**, with lesions affecting ≥1 high-impact site (scalp, face, skin folds, or genitals) that had failed ≥1 topical therapy

#### Study Design



#### Baseline Characteristics

##### GUS



7.6%

Average BSA

##### PBO

7.5%

Average BSA

#### Previous PsO Medications for All Patients

100%

Topical Therapies

18.5%

Photo-therapy

14%

Systemics

4.5%

Advanced Orals

BSA, body surface area; GUS, guselkumab; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index; PBO, placebo; PsO, psoriasis.

# SPECTREM: Skin Clearance Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Plaque Psoriasis


Richard G. Langley,<sup>1</sup> Linda Stein Gold,<sup>2</sup> Joseph F. Merola,<sup>3</sup> Kenneth B. Gordon,<sup>4</sup> Theodore Alkousakis,<sup>5</sup> Katelyn Rowland,<sup>5</sup> Daphne Chan,<sup>5</sup> Jenny Jeyarajah,<sup>5</sup> Laura Park-Wyllie,<sup>6</sup> Mark G. Lebwohl<sup>7</sup>

<sup>1</sup>Dalhousie University, Halifax, Nova Scotia, Canada; <sup>2</sup>Henry Ford Medical Center-Farmington Road, West Bloomfield, MI, USA; <sup>3</sup>UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, Texas, USA; <sup>4</sup>Medical College of Wisconsin, Milwaukee, WI, USA; <sup>5</sup>Johnson & Johnson, Horsham and Spring House, PA, USA; <sup>6</sup>Johnson & Johnson, Toronto, ON, Canada; <sup>7</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA




## WHAT WERE THE RESULTS?

The study showed that guselkumab was **well tolerated**, and guselkumab efficacy was **superior** vs placebo through Week 16. Guselkumab efficacy was maintained through Week 48.



At Week 16, 74% of participants had cleared or minimal psoriasis with GUS treatment; this efficacy was maintained through Week 48



About 7 out of 10 participants had 90% or greater improvement in PASI (PASI 90) at Week 48

### Glossary of terms

|                  |                                                                                   |                   |                                                                                                                                                                                                  |                                          |                                                                                                                                                 |
|------------------|-----------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Guselkumab (GUS) | An anti-IL-23p19 monoclonal antibody used to treat psoriasis                      | High-impact sites | Areas of the body such as the scalp, face, skin folds, and genitals. When these areas are affected by psoriasis, the disease often has very large negative effects on patients' quality of life. | Investigator's Global Assessment (IGA)   | A tool used to rate the severity of psoriasis on a scale from 0 (clear) to 4 (severe)                                                           |
| Psoriasis (PsO)  | A chronic skin condition characterized by red or purple, itchy, and scaly plaques | Placebo (PBO)     | A substance with no therapeutic effect used as a control                                                                                                                                         | Psoriasis Area and Severity Index (PASI) | A tool used to measure the severity and extent of psoriasis on a scale from 0 to 72. PASI 90 means that patients had at least 90% clearer skin. |



Scan the QR code for the full poster